@article { author = {Kassem, Neemat M and Makar, Wael S and Kassem, Hebatallah A and Talima, Soha and Tarek, Mustafa and Hesham, Hadeer and El-Desouky, Mohamed A}, title = {Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {20}, number = {9}, pages = {2749-2755}, year = {2019}, publisher = {West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.}, issn = {1513-7368}, eissn = {2476-762X}, doi = {10.31557/APJCP.2019.20.9.2749}, abstract = {Background: Breast cancer (BC) is the second most common cancer worldwide. MicroRNAs are a group ofnon-coding, single stranded RNAs of ~ 22 nucleotides, which regulate gene expression at the post-transcriptional level.Circulating miRNAs have been found as potential blood based predictive biomarkers. Purpose: we aim to evaluatemiR-34a and miR-125b to predict outcome from neoadjuvant chemotherapy in Egyptian BC patients. Methodology:Quantitative assessment of plasma miR-34a and miR-125b expression was performed by qRT-PCR. Thirty ninenewly diagnosed locally advanced BC female patients with 10 age and sex matched healthy volunteers were includedin the study. Results: We performed ROC curve analysis to evaluate the diagnostic value for the miR-34a withAUCs = 0.995, cutoff point of 2.57 sensitivity 97.4%, specificity 100%, PPV 100%, NPV 83.3% and accuracy 97.7%.miR-125b had AUC = 0.68 and a cutoff point of 8.69 with sensitivity 66.7%, specificity 70.0%, PPV 90.6%, NPV41.2% and accuracy 73.5%. miR-34a expression were significantly higher in BC patients compared to controls with pvalue <0.001*. Also, miR-34a expression level was significantly higher in patients with progressive disease with P value=0.03*. However, miR-125b expression levels were insignificantly higher in responsive patients with p value = 0.2.Conclusion: miRNAs are crucial candidates for novel molecular targeted therapies due to their capability to regulatenumerous genes in molecular pathways. Our data suggest that circulating miR-34a and miR-125b expression levelscould be promising highly accurate non-invasive biomarkers in diagnosing BCs. miR-34a can predict chemotherapeuticresistance associated with higher expression levels in non-responsive patients.}, keywords = {breast cancer,Circulating microRNA,Biomarker,Neoadjuvant chemotherapy}, url = {https://journal.waocp.org/article_88737.html}, eprint = {https://journal.waocp.org/article_88737_bcae5dc35603dce875f30eca9050cc47.pdf} }